Noah Medical Raises $150M to Scale Endoluminal Robotics Solutions

Noah Medical is $150 million richer these days.

The next-generation robotics firm has raised $150 million in Series B funding from various well-known institutional and strategic investors. The company intends to use the funds to meet rising demand for the Galaxy System, its next-generation, integrated solution for navigated robotic bronchoscopy.

“We are a mission driven startup and appreciate our investors’ support to allow us to scale and deliver on the future of medical robotics,” Noah Medical Founder/CEO Jian Zhang, Ph.D., said. “Next-generation robotics platforms like the Galaxy System are filling procedural gaps to provide superior clinical values to better serve customers’ needs. We are excited to welcome these investors to the team and are eager to grow and serve even more patients and clinicians.”
 
Led by the Softbank Vision Fund, and co-led by the Prosperity7 Ventures, the oversubscribed round also included investments from Tiger Global, and existing investors including Hillhouse, Sequoia China, Shangbay Capital, Uphonest Capital, Sunmed Capital, Lyfe Capital, 1955 Capital, and AME cloud ventures, as well as undisclosed strategic investors.
 
The announcement of this infusion of capital follows a series of recent milestone achievements for the Galaxy System, which is designed to improve location accuracy and successful diagnosis of lung nodules using its proprietary TiLT+ Technology. The platform received U.S. Food and Drug Administration clearance for commercial use in the United States and that it has initiated first-in-human trials at Macquarie University Hospital in Sydney, Australia. 
 
The Galaxy System—which features TiLT+Technology with integrated tomosynthesis and augmented fluoroscopy, a single-use disposable bronchoscope, and a small, compact footprint to allow for improved procedural workflow—is poised to disrupt the lung biopsy market.
 
Noah Medical aims to deliver adoptable clinical solutions through innovative endoluminal technologies. Based in Silicon Valley and backed by well-known institutional investors, its team of engineers, innovators and industry leaders bring years of experience from the world’s top robotics, medical device and healthcare companies.